Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: An analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data

N. N. Hanna, E. Onukwugha, M. A. Choti, A. J. Davidoff, I. H. Zuckerman, V. D. Hsu, C. D. Mullins

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim The prognostic effects of chemotherapy and various lymph node measures [positive nodes, total node count and the positive lymph node ratio (PLNR)] have been established. It is unknown whether the cancer-specific survival benefit of chemotherapy differs across these nodal prognostic categories. Method This retrospective analysis of linked Surveillance, Epidemiology and End Results (SEER) data and Medicare data (SEER-Medicare)included patients ≥ 65years of age with a diagnosis of stage III colon cancer between 1997 and 2002. We grouped patients according to the number of positive nodes (N1 and N2), total node count (≥12 and <12 total nodes) and PLNR (below the 75th percentile and at least at the 75th percentile of the PLNR). The end point was colon cancer-specific mortality. Results Fifty-one per cent (3701) of the 7263 patients received adjuvant therapy during the time period 1997-2002. The mean (standard deviation) number of total nodes examined was 13 (9) and the number of positive nodes identified was 3 (3). Patients with N2 disease, <12 total nodes examined and a high PLNR had a worse survival at 2, 3 and 5years following colectomy. Utilization of chemotherapy demonstrated a colon cancer-specific survival benefit (hazard ratio at median follow up=0.7; P<0.001) that was consistent and statistically significant across the three nodal prognostic categories examined. Conclusion The benefit of chemotherapy did not vary based on N stage, total node count or PLNR. The results favour a broad-based approach towards increasing the chemotherapy treatment rates in stage III patients of ≥ 65years of age, rather than an approach that targets clinical subgroups.

Original languageEnglish (US)
Pages (from-to)48-55
Number of pages8
JournalColorectal Disease
Volume14
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Adjuvant Chemotherapy
Medicare
Colonic Neoplasms
Epidemiology
Lymph Nodes
Survival
Drug Therapy
Colectomy
Mortality
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Colon cancer
  • Node ratio
  • Positive nodes
  • Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years : An analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data. / Hanna, N. N.; Onukwugha, E.; Choti, M. A.; Davidoff, A. J.; Zuckerman, I. H.; Hsu, V. D.; Mullins, C. D.

In: Colorectal Disease, Vol. 14, No. 1, 01.2012, p. 48-55.

Research output: Contribution to journalArticle

@article{faa7f57f992c4870acddb8286bc15efb,
title = "Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: An analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data",
abstract = "Aim The prognostic effects of chemotherapy and various lymph node measures [positive nodes, total node count and the positive lymph node ratio (PLNR)] have been established. It is unknown whether the cancer-specific survival benefit of chemotherapy differs across these nodal prognostic categories. Method This retrospective analysis of linked Surveillance, Epidemiology and End Results (SEER) data and Medicare data (SEER-Medicare)included patients ≥ 65years of age with a diagnosis of stage III colon cancer between 1997 and 2002. We grouped patients according to the number of positive nodes (N1 and N2), total node count (≥12 and <12 total nodes) and PLNR (below the 75th percentile and at least at the 75th percentile of the PLNR). The end point was colon cancer-specific mortality. Results Fifty-one per cent (3701) of the 7263 patients received adjuvant therapy during the time period 1997-2002. The mean (standard deviation) number of total nodes examined was 13 (9) and the number of positive nodes identified was 3 (3). Patients with N2 disease, <12 total nodes examined and a high PLNR had a worse survival at 2, 3 and 5years following colectomy. Utilization of chemotherapy demonstrated a colon cancer-specific survival benefit (hazard ratio at median follow up=0.7; P<0.001) that was consistent and statistically significant across the three nodal prognostic categories examined. Conclusion The benefit of chemotherapy did not vary based on N stage, total node count or PLNR. The results favour a broad-based approach towards increasing the chemotherapy treatment rates in stage III patients of ≥ 65years of age, rather than an approach that targets clinical subgroups.",
keywords = "Chemotherapy, Colon cancer, Node ratio, Positive nodes, Survival",
author = "Hanna, {N. N.} and E. Onukwugha and Choti, {M. A.} and Davidoff, {A. J.} and Zuckerman, {I. H.} and Hsu, {V. D.} and Mullins, {C. D.}",
year = "2012",
month = "1",
doi = "10.1111/j.1463-1318.2011.02545.x",
language = "English (US)",
volume = "14",
pages = "48--55",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years

T2 - An analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data

AU - Hanna, N. N.

AU - Onukwugha, E.

AU - Choti, M. A.

AU - Davidoff, A. J.

AU - Zuckerman, I. H.

AU - Hsu, V. D.

AU - Mullins, C. D.

PY - 2012/1

Y1 - 2012/1

N2 - Aim The prognostic effects of chemotherapy and various lymph node measures [positive nodes, total node count and the positive lymph node ratio (PLNR)] have been established. It is unknown whether the cancer-specific survival benefit of chemotherapy differs across these nodal prognostic categories. Method This retrospective analysis of linked Surveillance, Epidemiology and End Results (SEER) data and Medicare data (SEER-Medicare)included patients ≥ 65years of age with a diagnosis of stage III colon cancer between 1997 and 2002. We grouped patients according to the number of positive nodes (N1 and N2), total node count (≥12 and <12 total nodes) and PLNR (below the 75th percentile and at least at the 75th percentile of the PLNR). The end point was colon cancer-specific mortality. Results Fifty-one per cent (3701) of the 7263 patients received adjuvant therapy during the time period 1997-2002. The mean (standard deviation) number of total nodes examined was 13 (9) and the number of positive nodes identified was 3 (3). Patients with N2 disease, <12 total nodes examined and a high PLNR had a worse survival at 2, 3 and 5years following colectomy. Utilization of chemotherapy demonstrated a colon cancer-specific survival benefit (hazard ratio at median follow up=0.7; P<0.001) that was consistent and statistically significant across the three nodal prognostic categories examined. Conclusion The benefit of chemotherapy did not vary based on N stage, total node count or PLNR. The results favour a broad-based approach towards increasing the chemotherapy treatment rates in stage III patients of ≥ 65years of age, rather than an approach that targets clinical subgroups.

AB - Aim The prognostic effects of chemotherapy and various lymph node measures [positive nodes, total node count and the positive lymph node ratio (PLNR)] have been established. It is unknown whether the cancer-specific survival benefit of chemotherapy differs across these nodal prognostic categories. Method This retrospective analysis of linked Surveillance, Epidemiology and End Results (SEER) data and Medicare data (SEER-Medicare)included patients ≥ 65years of age with a diagnosis of stage III colon cancer between 1997 and 2002. We grouped patients according to the number of positive nodes (N1 and N2), total node count (≥12 and <12 total nodes) and PLNR (below the 75th percentile and at least at the 75th percentile of the PLNR). The end point was colon cancer-specific mortality. Results Fifty-one per cent (3701) of the 7263 patients received adjuvant therapy during the time period 1997-2002. The mean (standard deviation) number of total nodes examined was 13 (9) and the number of positive nodes identified was 3 (3). Patients with N2 disease, <12 total nodes examined and a high PLNR had a worse survival at 2, 3 and 5years following colectomy. Utilization of chemotherapy demonstrated a colon cancer-specific survival benefit (hazard ratio at median follow up=0.7; P<0.001) that was consistent and statistically significant across the three nodal prognostic categories examined. Conclusion The benefit of chemotherapy did not vary based on N stage, total node count or PLNR. The results favour a broad-based approach towards increasing the chemotherapy treatment rates in stage III patients of ≥ 65years of age, rather than an approach that targets clinical subgroups.

KW - Chemotherapy

KW - Colon cancer

KW - Node ratio

KW - Positive nodes

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=83255187968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83255187968&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1318.2011.02545.x

DO - 10.1111/j.1463-1318.2011.02545.x

M3 - Article

C2 - 21689262

AN - SCOPUS:83255187968

VL - 14

SP - 48

EP - 55

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 1

ER -